Abstract: The present invention relates to a process for preparation of crystalline Form-SDI of Dasatinib (I). Said crystalline Form-SDI of Dasatinib is characterized by X-ray powder diffraction pattern comprising of at least seven 2?° peaks selected from the XRPD peak set of 5.8, 11.5, 12.7, 13.2, 17.3, 17.5, 18.1, 20.1, 20.5, 22.1, 25.4, 26.6, 26.8±0.20 2?°; IR spectrum having at least five absorption peaks selected from about 3390 cm?1, 2923 cm?1, 1621 cm?1, 1615 cm?1, 1537 cm?1, 1316 cm?1, 1061 cm?1, 815 cm?1 and 783 cm?1; and DSC isotherm comprising at least two endothermic peaks ranging between ?130° C. to 150° C., 160° C. to 175° C. or 280° C. to 290° C. The pharmaceutical compositions of the crystalline Form-SDI of Dasatinib or its hydrate thereof may be useful as an anti-cancer agent.